• An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
Auteur:Bonnefoi, H; Biganzoli, Laura; Cufer, T; Mauriac, L; Hamilton, Andrew; Schaefer, P; Piccart-Gebhart, Martine
Informations sur la publication:Breast cancer research and treatment, 70, 1, page (55-63)
Statut de publication:Publié, 2001-11
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Antibiotics, Antineoplastic -- administration & dosage
Antimetabolites, Antineoplastic -- administration & dosage
Antineoplastic Agents, Alkylating -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- pathology
Breast Neoplasms -- surgery
Cyclophosphamide -- administration & dosage
Drug Administration Schedule
Epirubicin -- administration & dosage
Fluorouracil -- administration & dosage
Injections, Intravenous
Middle Aged
Severity of Illness Index
Treatment Outcome
Note générale:Clinical Trial
Clinical Trial, Phase I
Journal Article